However, due to the limited number of samples, the accuracy of NALCN promoter methylation as a prognostic or diagnostic biomarker in the plasma of lung cancer patients is expected to improve with the use of a sufficient number of samples. This evidence concerns the gene NALCN and lung carcinoma.